Neuropathic cancer pain is common, very disabling and difficult to treat. It can be related to tumor invasion of neural structures and neuronal damage by surgery, chemotherapy and radiation therapy. Adjuvant analgesics are often used with opioids to control neuropathic pain in cancer patients. Methadone, a synthetic opioid with multiple mechanisms of action, is gaining increasing importance as an effective agent in the treatment of cancer related neuropathic pain. This case illustrates the challenges of managing severe pain in a patient with head and neck cancer while undergoing anti-tumor treatment. A review of the adjuvant analgesics and opioids, particularly methadone, in the management of neuropathic pain is also included.
MorleyJSMakinMK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev. 1998;5(1):51–58.
2.
GilronIWatsonCPNCahillCMMoulinDE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175(3):265–275.
3.
GrondSRedbruchLMeuserTSabatowskiRLoickGLehmannKA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79(1):15–20.
4.
SchmaderKE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354.
5.
TalmiYPWallerABercoviciM. Pain experienced by patients with terminal head and neck carcinoma. Cancer. 1997;80(6):1117–1123.
6.
GrondSZechDDiefenbachCRadbruchLLehmannKA. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64(1):107–114.
DworkinRHO’ConnorABAudetteJ. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 suppl):S3–S14.
10.
DavisMP. What is new in neuropathic pain?Support Care Cancer. 2007;15(4):363–372.
11.
RowbothamMHardenNStaceyBBernsteinPMagnus-MillerL. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–1842.
12.
TaiZKirshblumSChenBMillisSJonhstonMDeLisaJA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25(2):100–105.
13.
SerpellMG. Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain. 2002;99(3):557–566.
14.
GordhTEStubhaugAJensenTS. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain. 2008;138(2):255–266.
15.
McDonaldAAPortenoyRK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Support Oncology. 2006;4(1):43–52.
16.
KeskinboraKPekelAFAydinliI. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage. 2007;34(2):183–189.
17.
CaraceniAZeccaEBonezziC. Gapabentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22(14):2909–2917.
18.
TölleTFreynhagenRVersavelMTrostmannUYoungJPJrPregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12(2):203–213.
19.
RichterRWPortenoyRSharmaULaMoreauxLBockbraderHKnappLE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253–260.
20.
SabatowskiRGalvezRCherryDA. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain. 2004;109(1-2):26–35.
21.
DworkinRHCorbinAEYoungJPJr, Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274–1283.
22.
VrankenJHDijkgraafMGKruisMRvan der VegtMHHollmannMWHeesenM. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136(1-2):150–157.
23.
SindrupSHOttoMFinnerupNBJensenTS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96(6):399–409.
24.
SaartoTWiffenPJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(2):CD005454. doi 10.1002/14651858.
25.
GilronIBaileyJMDongshengTHoldenRRJacksonACHouldenRL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252–1261.
26.
RowbothamMCGoliVKunzNRLeiD. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697–706.
27.
SindrupSHBachFWMadsenCGramLFJensenTS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60(8):1284–1289.
28.
TasmuthTHartelBKalsoE. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6(1):17–24.
29.
GrotheDrSchecknerBAlbanoD. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. 2004;24(5):621–629.
30.
KajdaszDKIyengarSDesaiahD. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(suppl):S2536–S2546.
31.
RaskinJPritchettYLWangF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346–356.
32.
MeierTWasnerGFaustM. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1-2):151–158.
33.
BinderABruxelleJRogersPHansGBoeslIBaronR. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393–408.
34.
BaronRMayoralVLeijonGBinderASteigerwaldISerpellM. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231–241.
35.
GammaitoniARDavisMW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother.2002;36(2):236–240.
36.
KongVKFIrwinMG. Adjuvant analgesics in neuropathic pain. Eur J Anaesthesiol. 2009;26(2):96–100.
37.
BaronRJanigW. Adrenergic and cholinergic targets in pain pharmacology. In: BeaulieuPLussierDPorrecaFDickensonAH, eds. Pharmacology of Pain. Seattle, WA: IASP Press; 2010:347–381.
38.
MoulinDEClarkAJGilronI. Pharmacological management of chronic neuropathic pain–Consensus statement and guidelines from the canadian pain society. Pain Res Manage. 2007;12(1):13–21.
39.
Nunez OlarteJM. Oxycodone and the callenge of neuropathic cancer pain; a review. Oncology. 2008;74(1 suppl):S83–S90.
40.
GilronIBaileyJMTuDHoldenRRWeaverDFHouldenRL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324–1334.
41.
HannaMO’BrienCWilsonMC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12(6):804–813.
42.
GattiASabatoAFOcchioniRBaldeshiGCRealeC. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol. 2009;61(3):129–137.
43.
DavisMQuigleyC. Methadone. In: DavisMGlarePQuigleyCHardyJR, eds. Opioids in Cancer Pain. 2nd ed. New York, NY: Oxford University Press; 2009:211–243.
44.
LeppertW. The role of methadone in cancer pain treatment–a review. Intl J Clin Pract. 2009;63(7):1095–1109.
45.
KrantzMJMartinJStimmelBMehtaDHaigneyMCP. QTc interval screening in methadone treatment. Ann Int Med. 2009;150(6):387–395.
46.
ClearyJF. The pharmacologic management of cancer pain. J Pall Med. 2007;10(6):1369–1394.
47.
GagnonBAbdulazizASchrierG. Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003;8(3):149–154.
48.
MorleyJSBridsonJNashTPMilesJBWhiteSMakinMK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17(7):576–587.
49.
MoulinDPalmaDWatlingCSchulzV. Methadone in the management of intractable neuropathic non cancer pain. Can J Neuro Sci. 2005;32(3):340–343.
50.
AltierNDionDBoulangerAChoiniereM. Management of neuropathic pain with methadone: a review of 13 cases. Clin J Pain. 2005;21(4):364–369.
51.
ManninoRCoynePSwaineyCHansenLALyckholmL. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag. 2006;2(5):269–276.
52.
LeggeJBallNElliottDP. The potential role of ketamine in hospice analgesia: a literature review. Consult Pharm. 2006;21(1):51–57.
53.
ChungWJ. Successful use of ketamine infusion in the treatment of intractable cancer pain in an outpatient. J Pain Symptom Manage. 2007;33(1):2–5.
54.
BellRFEcclestonCKalsoEA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2003;(1):CD003351. doi: 10.1002/14651858.
55.
JostLRoilaF.Management of cancer pain: EMO clinical practice guidelines. Ann Oncol. 2010;21(5 suppl):S257–S260.
56.
SvendsenKBJensenTSBachFW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. BMJ. 2004;329(7460):253–261.
57.
WallaceJM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep. 2007;11(3):208–214.
58.
NurmikkoTJSerpellMGHoggartBToomeyPJMorlionBJHainesD. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210–220.
59.
DrayAPerkinsMN. New pain treatments in late development. In: BeaulieuPLussierDPorrecaFDickensonAH, eds. Pharmacology of Pain. Seattle, WA: IASP Press; 2010:383–401.
